# 31 May 2018 Report Review of May. 2018



## Hong Kong | INVESTNOTES REPORTS REVIEW

Sectors: Air, Automobiles (ZhangJing), Healthcare & Consuming (Eurus Zhou), TMT, Education and Financial (Terry Li)

## Automobile & Air (ZhangJing)

This month I released 4 reports including 3 updated reports and 1 NDR takeaways: GreatWall Motor (2333. HK), BYD (1211. HK), Geely (175. HK),

FDG (729. HK). Among which , we prefer Geely.

There are four models of Geely with a monthly sales volume of over 10,000 in 2017, two of which reported a sales volume of over 20,000. Since the beginning of 2018, the main models remain attractive and the newly launched models are gaining popularity step by step. It is expected that the number of models with a monthly sales volume of over 10,000 will increase to 5 or 6, and the number of models with a sales volume of over 20,000 will increase to 3. We believe that Geely will continue to be benefited from the dividends generated by successful strategies. The Company shows advantages in epitaxial leapfrog development and export market. Several times of increases in the management's holdings also demonstrate its considerable confidence.In terms of valuation, we increase the profit forecast, adjusting our target price to HK\$36, equivalent to 18/13 P/E ratio in 2018/2019, and we shall give the rating of Buy.

#### Healthcare & Consuming (Eurus Zhou)

This month I released 3 equity reports, including SPH (2607HK), CSPC (1093HK) and Netdragon (777HK). We tend to highly recommend Netdragon 777HK) and SPH (2607HK). Netdragon, a leading online education firm, announced the acquisition of EDMODO (a global education online platform to K-12 schools) with a consideration of USD137.5mn. We are positive on the synergies among Netdragon's current products (education software and hardware) and EDOMODO's large user base, which is believed to form great monetization potential in future. For SPH, it announced FY17&18Q1 results, beat our expectation. We see that momentum of manufacturing maintains strong and growth of retail business steps up. We highlight that consistency evaluation provides future driver. China government published policies to facilitate the replacement of original imported drug with generic drug. It indicates that qualified generic drugs should be included into public purchase lists and be paid just as original drugs. We highlight that passing the evaluation will increase sales volume and ASP in future.

## **Education (Terry Li)**

I released a report on China New Higher Education Group in this month. The group is a leading higher education operator in China, with six schools in Yunnan, Guizhou, Xinjiang, Heilongjiang, Hubei, Henan, and one under construction in Gansu. Thanks to the robust economic growth in China and the universal in higher education, we believe the demand on higher education will become higher. Although the number of candidate for Gaokao has peaked in 2008 due to the low birth rate, some provinces still record increasing candidates for Gaokao, where four out of seven schools for the group are located in such provinces. Thus, we are positive to the growth in student enrollment for the group in the next two or three years.

## Review report 31 May 2018

## Fig 1. Performance of Recommended Stocks



					Price on			Last			
					Recom		Expect	Month	Last	Closing	
					mendati	Target	ed	Closing	Month	Price	1M Price
Time	Ticker	Company	Analyst	Rating	on Date	Price	Return	Price	Return	2M ago	Chg
2018/5/4	2333 HK	GWM	ZJ	Accumulate	8.22	9.6	16.79%	7.75	-5.72%	8.02	-3.37%
2018/5/9	2607 HK	Shanghai Pharma	EU	Accumulate	21.8	25.5	16.97%	23.2	6.42%	21.55	7.66%
2018/5/14	1211 HK	BYD	ZJ	Accumulate	52.05	60	15.27%	50.75	-2.50%	55.15	-7.98%
2018/5/16	1093 HK	CSPC	EU	Accumulate	22	24.8	12.73%	24.75	12.50%	20.2	22.52%
2018/5/18	175 HK	Geely	ZJ	Buy	23.2	36	55.17%	22.75	-1.94%	21	8.33%
2018/5/23	777 HK	Netdragon	EU	Buy	19.6	35.7	82.14%	20.4	4.08%	18.99	7.42%
2018/5/25	2001 HK	China New Higher Education	rТЕ	Accumulate	7.3	8.19	12.19%	7.46	2.19%	5.82	28.18%
2018/5/29	729 HK	FDG	ZJ	NA	0.165	NA	NA	0.166	0.61%	0.248	-33.06%

A stock is calculated by RMB yuan.

Source: Company, Phillip Securities Research

## Review report 31 May 2018



#### PHILLIP RESEARCH STOCK SELECTION SYSTEMS

Total Return	Recommendation	Rating	Remarks
>+20%	Buy	1	>20% upside from the current price
+5% to +20%	Accumulate	2	+5% to +20%upside from the current price
-5% to +5%	Neutral	3	Trade within ± 5% from the current price
-5% to -20%	Reduce	4	-5% to -20% downside from the current price
<-20%	Sell	5	>20%downside from the current price

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation

#### **GENERAL DISCLAIMER**

This publication is prepared by Phillip Securities (Hong Kong) Ltd ("Phillip Securities"). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below.

This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or consequential loss arising from any use of material contained in this publication.

The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the "Research") contained in this publication are based on such information and are expressions of belief only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice.

This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This publication should not be relied upon as authoritative without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research should take into account existing public information, including any registered prospectus in respect of such security.

#### **Disclosure of Interest**

Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this report.

Firm's Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation.

#### Availability

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited ("PSHK") believed to be accurate. PSHK does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk.

© 2018 Phillip Securities (Hong Kong) Limited

## Review report 31 May 2018

## **Contact Information (Regional Member Companies)**

SINGAPORE Phillip Securities Pte Ltd Raffles City Tower 250, North Bridge Road #06-00 Singapore 179101 Tel : (65) 6533 6001

Fax : (65) 6535 6631 Website: <u>www.poems.com.sg</u>

## HONG KONG Phillip Securities (HK) Ltd

Exchange Participant of the Stock Exchange of Hong Kong 11/F United Centre 95 Queensway Hong Kong Tel (852) 22776600 Fax (852) 28685307 Websites: www.phillip.com.hk

> INDONESIA PT Phillip Securities Indonesia ANZ Tower Level 23B, JI Jend Sudirman Kav 33A Jakarta 10220 – Indonesia Tel (62-21) 57900800 Fax (62-21) 57900809 Website: www.phillip.co.id

## THAILAND

Phillip Securities (Thailand) Public Co. Ltd 15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel (66-2) 6351700 / 22680999 Fax (66-2) 22680921 Website www.phillip.co.th

### UNITED KINGDOM

King & Shaxson Capital Limited 6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel (44-20) 7426 5950 Fax (44-20) 7626 1757 Website: www.kingandshaxson.com

AUSTRALIA PhillipCapital Australia Level 12, 15 William Street, Melbourne, Victoria 3000, Australia Tel (613) 96188238 Fax (613) 92002272 Website: www.phillipcapital.com.au



#### MALAYSIA

Phillip Capital Management Sdn Bhd B-3-6 Block B Level 3 Megan Avenue II, Number 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur Tel (603) 21628841 Fax (603) 21665099 Website: www.poems.com.my

#### JAPAN

PhillipCapital Japan K.K. Nagata-cho Bldg., 8F, 2-4-3 Nagata-cho, Chiyoda-ku, Tokyo 100-0014 Tel (81-3) 35953631 Fax (81-3) 35953630 Website:<u>www.phillip.co.jp</u>

CHINA

Phillip Financial Advisory (Shanghai) Co. Ltd No 436 Heng Feng Road, Green Tech Tower Unit 604, Postal code 200070 Tel (86-21) 51699400 Fax (86-21) 60911155 Website: www.phillip.com.cn

FRANCE

King & Shaxson Capital Limited 3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France Tel (33-1) 45633100 Fax (33-1) 45636017 Website: www.kingandshaxson.com

## UNITED STATES

Phillip Futures Inc 141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA Tel +1.312.356.9000 Fax +1.312.356.9005